ArriVent BioPharma (AVBP) Stock Price Target 2026

The average analyst price target for ArriVent BioPharma is $32.71, 127.8% above the current price. Of 12 analysts, 12 rate it Buy. Targets range from $18 to $50. The latest change came on Oct 27, 2026, when Guggenheim raised its price target on ArriVent BioPharma from $18 to $30 and kept a Buy rating.

The Average Analyst Price Target for ArriVent BioPharma is $32.71.

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

12Buy

Consensus RatingBuy# Analysts12Avg. Consensus PT$32.71Upside to Avg. PT+127.8%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for ArriVent BioPharma Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 27, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$18→$30
Oct 20, 2026	B. Riley Securities	Kalpit Patel	PT Cut	Buy	$45→$29
Oct 16, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$29
Oct 8, 2026	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$47→$27
Oct 7, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$40→$20
Oct 7, 2026	Jones Trading	Soumit Roy	PT Cut	Buy	$45→$22
Oct 7, 2026	Truist Securities	Supawat Thongthip	PT Cut	Buy	$45→$18
Oct 7, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$45→$18
Oct 7, 2026	BTIG	Jeet Mukherjee	PT Cut	Buy	$42→$29
Aug 17, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$44→$47
Aug 13, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$43→$40
Aug 13, 2026	Guggenheim	Michael Schmitz	Maintained	Buy	$45
Aug 13, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$42
May 29, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$43→$45
May 13, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$45→$43
Apr 24, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$33→$45
Mar 23, 2026	B. Riley Securities	Kalpit Patel	PT Raise	Buy	$37→$45
Mar 12, 2026	BTIG	Jeet Mukherjee	Assumes	Buy	$42
Mar 6, 2026	Oppenheimer	Jeff Jones	PT Raise	Outperform	$44→$50
Mar 6, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$31→$33